Payment overview · 2025
General Payments
$814.32
44 reported records · 16 companies
Healthcare provider profile · identity verified
Wesley Moore, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · HODGENVILLE, KY · NPI 1053792069
Verified facts
What the public records show
CMS Open Payments records show Wesley Moore, D.O. received $814.32 in general payments during 2025 across 44 reported records.
Medtronic, Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$154.97 | 19.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $136.25 | 16.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.00 | 9.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.14 | 7.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $58.25 | 7.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.54 | 6.5% | 3 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $44.05 | 5.4% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.66 | 4.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.20 | 4.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.51 | 4.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.03 | 3.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.03 | 2.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.31 | 2.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.99 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.73 | 2.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.66 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $814.32 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $154.97 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.78 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.14 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.39 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $58.25 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.54 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $50.06 | 3 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $44.05 | 3 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.66 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.47 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 164 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 479 | 106 |
| Omeprazole | Omeprazole | 333 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 76 |
| Furosemide | Furosemide | 293 | 79 |
| Lisinopril | Lisinopril | 287 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 256 | 64 |
| Losartan Potassium | Losartan Potassium | 237 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 63 |
| Gabapentin | Gabapentin | 234 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 232 | 77 |
| Montelukast Sodium | Montelukast Sodium | 215 | 49 |
| Metformin Hcl | Metformin Hcl | 213 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 47 |
| Trazodone Hcl | Trazodone Hcl | 186 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 171 | 43 |
| Potassium Chloride | Potassium Chloride | 167 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 166 | 39 |
| Eliquis | Apixaban | 164 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 38 |
| Carvedilol | Carvedilol | 158 | 32 |
| Sertraline Hcl | Sertraline Hcl | 153 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 35 |
| Prednisone | Prednisone | 128 | 89 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 28 |
| Buspirone Hcl | Buspirone Hcl | 120 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 17 |
| Bupropion Xl | Bupropion Hcl | 114 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 26 |
| Allopurinol | Allopurinol | 103 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 32 |
| Mounjaro | Tirzepatide | 98 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 96 | 28 |
| Jardiance | Empagliflozin | 95 | 14 |
| Januvia | Sitagliptin Phosphate | 89 | 15 |
| Lorazepam | Lorazepam | 87 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 30 |
| Meloxicam | Meloxicam | 81 | 24 |
| Metformin Hcl Er | Metformin Hcl | 81 | 24 |
| Atenolol | Atenolol | 78 | 21 |
| Cefdinir | Cefdinir | 78 | 63 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 20 |
| Ozempic | Semaglutide | 78 | 18 |
| Simvastatin | Simvastatin | 76 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 16 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 71 | 18 |
| Glimepiride | Glimepiride | 70 | suppressed |
| Famotidine | Famotidine | 68 | 15 |
| Linzess | Linaclotide | 66 | 17 |
| Alendronate Sodium | Alendronate Sodium | 65 | 17 |
| Donepezil Hcl | Donepezil Hcl | 65 | 14 |
| Mirtazapine | Mirtazapine | 64 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 17 |
| Spironolactone | Spironolactone | 64 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 62 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 58 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 12 |
| Ezetimibe | Ezetimibe | 57 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 14 |
| Temazepam | Temazepam | 56 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 55 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 12 |
| Alprazolam | Alprazolam | 49 | 11 |
| Celecoxib | Celecoxib | 49 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 32 |
| Bumetanide | Bumetanide | 48 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 34 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 17 |
| Baclofen | Baclofen | 43 | 11 |
| Cephalexin | Cephalexin | 43 | 28 |
| Azithromycin | Azithromycin | 41 | 36 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 13 |
| Azelastine Hcl | Azelastine Hcl | 38 | 12 |
| Naproxen | Naproxen | 38 | 14 |
| Promethazine Hcl | Promethazine Hcl | 38 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Estradiol | Estradiol | 37 | 11 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 36 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 27 |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 25 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Diazepam | Diazepam | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 15 |
| Roflumilast | Roflumilast | 27 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $814.32 · 44 records | Medtronic, Inc. | AUSTEDO XR, Auvelity, Cologuard Collection Kit, ELIQUIS, ENDURANT IIS, EOHILIA, JATENZO, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error